Zannella, C.; Chianese, A.; Monti, A.; Giugliano, R.; Morone, M.V.; Secci, F.; Sanna, G.; Manzin, A.; De Filippis, A.; Doti, N.;
et al. SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection. Pharmaceutics 2023, 15, 2791.
https://doi.org/10.3390/pharmaceutics15122791
AMA Style
Zannella C, Chianese A, Monti A, Giugliano R, Morone MV, Secci F, Sanna G, Manzin A, De Filippis A, Doti N,
et al. SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection. Pharmaceutics. 2023; 15(12):2791.
https://doi.org/10.3390/pharmaceutics15122791
Chicago/Turabian Style
Zannella, Carla, Annalisa Chianese, Alessandra Monti, Rosa Giugliano, Maria Vittoria Morone, Francesco Secci, Giuseppina Sanna, Aldo Manzin, Anna De Filippis, Nunzianna Doti,
and et al. 2023. "SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection" Pharmaceutics 15, no. 12: 2791.
https://doi.org/10.3390/pharmaceutics15122791
APA Style
Zannella, C., Chianese, A., Monti, A., Giugliano, R., Morone, M. V., Secci, F., Sanna, G., Manzin, A., De Filippis, A., Doti, N., & Galdiero, M.
(2023). SARS-CoV-2 Fusion Peptide Conjugated to a Tetravalent Dendrimer Selectively Inhibits Viral Infection. Pharmaceutics, 15(12), 2791.
https://doi.org/10.3390/pharmaceutics15122791
